Protecting Skin from Chemical Threats
Oxidized lipids and microvesicle particles as effectors for chemical threats to skin
This grant explores how specific chemicals harm the skin and body, aiming to discover new ways to protect people from these effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project ID | NIH-11131215 on NIH RePORTER |
What this research studies
This grant focuses on understanding how chemical warfare agents, like arsenicals and nitrogen mustards, cause severe damage to the skin and other organs. Currently, there isn't a direct treatment to stop these harmful effects. Researchers believe that exposure to these chemicals, especially when combined with other stressors like alcohol or burns, creates harmful substances called Platelet-activating factor (PAF) and tiny signaling particles called microvesicle particles (MVP). These substances lead to inflammation and organ damage throughout the body. By understanding these detailed processes, the goal is to develop effective antidotes to protect people from chemical threats.
Who could benefit from this research
Good fit: This foundational research aims to benefit individuals who may be exposed to chemical warfare agents or similar toxic substances, potentially leading to future protective treatments.
Not a fit: Patients not exposed to or at risk from chemical warfare agents or similar toxic substances would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments or antidotes to prevent or reduce severe skin and organ damage caused by chemical exposures.
How similar studies have performed: Prior research has identified some of the harmful substances involved, but this grant aims to uncover detailed mechanisms to develop new antidotes.
Where this research is happening
Dayton, United States
- Wright State University — Dayton, United States (Active)
Researchers
- Principal investigator: Travers, Jeffrey B. — Wright State University
- Study coordinator: Travers, Jeffrey B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.